Welcome to our dedicated page for Ascendis Pharma A/S American Depositary Shares news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma A/S American Depositary Shares stock.
Ascendis Pharma A/S (NASDAQ: ASND) is a pioneering biotechnology company located at 12 Tuborg Blvd., Hellerup, Capital Region of Denmark, Denmark. Specializing in the development of prodrug therapies, Ascendis Pharma is leveraging its proprietary TransCon technology to create therapies with improved efficacy and safety profiles that address significant unmet medical needs. The company’s diverse product pipeline includes TransCon growth hormone, TransCon peptides, TransCon PTH, and TransCon CNP, among others.
Ascendis Pharma operates across North America, China, and Europe, with the majority of its revenue derived from North American markets. The firm’s flagship product, SKYTROFA, has become the leading growth hormone product by value in the U.S. Ascendis is also rolling out YORVIPATH in Europe, starting with Germany and Austria. In addition, the company is advancing its clinical program for TransCon CNP.
In 2023, Ascendis undertook a significant restructuring to streamline its operations, processes, and expense allocations. President and CEO Jan Mikkelsen maintains that Ascendis is on track to achieve its ambitious Vision 3x3 and Vision 2030 goals, which include achieving blockbuster status for each of its three independent Endocrinology Rare Disease products and expanding its engine for future innovation.
Financially, Ascendis Pharma reported substantial revenue growth in 2023, with total revenue reaching €266.7 million compared to €51.2 million in 2022. This growth was primarily driven by higher SKYTROFA revenue and an upfront payment from Teijin. Research and development (R&D) expenses also increased to €413.5 million in 2023, reflecting ongoing development activities in their TransCon programs. Despite a net loss for the year, the company's financial health remains robust, with cash, cash equivalents, and marketable securities totaling €399.4 million as of December 31, 2023.
Looking ahead, Ascendis Pharma has several key milestones slated for 2024, including the expected commercial launch of TransCon PTH in the U.S. and advancing its oncology and ophthalmology programs. The company also plans to achieve operating cash flow breakeven on a quarterly basis by the end of the year.
Ascendis continues to focus on leveraging its TransCon technology to develop therapies that can make a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis Pharma is committed to becoming a leading, fully integrated biopharma company.
Ascendis Pharma (ASND) announced Q2 2022 financial results, reporting total revenue of €6.2 million, a significant increase from €1.0 million year-over-year, driven by €4.4 million in SKYTROFA sales. The company holds €995 million in cash and equivalents, positioning it to achieve its Vision 3x3 strategy. The anticipated U.S. launch of TransCon PTH is set for mid-2023, with EU submissions planned shortly after. Although net loss for Q2 was €81.3 million, a decrease from €134.4 million in 2021, R&D and SG&A expenses rose due to increased operations. A conference call is scheduled for 4:30 PM ET.
Ascendis Pharma A/S (Nasdaq: ASND) will host a conference call and live webcast on August 10, 2022, at 4:30 p.m. ET to discuss its second quarter 2022 financial results and provide a business update. The event aims to showcase the company's commitment to transparency and investor engagement. Participants can access the webcast via the link provided, with a replay available for 30 days post-event. Ascendis Pharma is focused on developing innovative therapies using its TransCon technologies to improve patient outcomes.
Ascendis Pharma A/S (Nasdaq: ASND) announced significant advancements in its investigational product candidate TransCon PTH for adult hypoparathyroidism, showcasing Phase 2 and Phase 3 trial data at ENDO 2022. Dr. Aliya Khan reported that the PaTHway Trial highlighted a majority of treated patients achieving disease control, including normalized serum calcium and independence from conventional therapy. The treatment was well-tolerated. These presentations aim to reshape the treatment paradigm for hypoparathyroidism and underline Ascendis' commitment to innovative therapies.
Ascendis Pharma has announced new leadership appointments in its Endocrinology commercial team. Joe Kelly is appointed Head of U.S. Commercial, while Scott A. Holmes takes on the role of Head of Global Commercial Strategy. This follows the retirement of Jesper Høiland, who will continue as a senior advisor. The team aims to enhance U.S. market leadership for SKYTROFA and prepare for upcoming TransCon product launches. Despite the leadership change, the company focuses on leveraging its TransCon technologies to develop innovative therapies.
Ascendis Pharma A/S announced positive results from VISEN Pharmaceuticals' Phase 3 trial of TransCon™ hGH for pediatric growth hormone deficiency (GHD) in China. The trial met its primary endpoint, demonstrating significantly greater annualized height velocity at 52 weeks (p=0.0010) compared to daily growth hormone treatment. This result aligns with previous multinational trial outcomes, confirming the safety and efficacy of TransCon hGH. The treatment is now approved in the U.S. and EU. The CEO praised VISEN for its achievement, underscoring TransCon technology's global applicability.
Ascendis Pharma (ASND) reported strong Phase 3 trial results for its TransCon PTH therapy, potentially positioning it as the first replacement therapy for adults with hypoparathyroidism. The company anticipates U.S. FDA submission by Q3 2022 and EU MAA submission by Q4 2022. First-quarter revenue surged to €6.8 million, up from €0.7 million, mainly driven by SKYTROFA sales. However, the net loss widened to €125.5 million, or €2.21 per share. Ascendis ended Q1 2022 with €1,065 million in cash, bolstering its investment potential for growth and sustainability.
Ascendis Pharma A/S (Nasdaq: ASND) will attend the BofA Securities 2022 Healthcare Conference on May 12, 2022, in Las Vegas, NV. Company executives are set to participate in a fireside chat from 1:40-2:10 p.m. ET. A live webcast will be accessible on their website, with a replay available for 30 days post-event. Ascendis aims to leverage its platform technology to develop new therapies, focusing on making a significant impact in patients' lives.
Ascendis Pharma A/S (Nasdaq: ASND) has scheduled a conference call for May 11, 2022, at 4:30 p.m. ET to discuss its first quarter financial results. The event will provide an update on the company's operations and financial performance. Interested parties can join via a live webcast on Ascendis Pharma's website, with a replay available afterward for 30 days. Ascendis Pharma focuses on using its TransCon technologies to develop innovative therapies aimed at improving patient outcomes.
Ascendis Pharma A/S (Nasdaq: ASND) announced new clinical data presentations at four medical meetings in May 2022. Key highlights include Phase 3 results for children with growth hormone deficiency treated with TransCon hGH for 2.5 years, and findings on comorbidities in adults with growth hormone deficiency. At the PES 2022 meeting, an oral presentation will detail the efficacy and safety of lonapegsomatropin in children. Additionally, the company’s FDA-approved treatment, SKYTROFA, will be showcased. This data signifies the expansion of Ascendis’ endocrinology portfolio.
Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of a private offering of US$500 million in 2.25% convertible senior notes due 2028, set to settle on March 29, 2022. An additional US$75 million may be purchased by initial buyers within 13 days. The notes will accrue interest semi-annually and are convertible into ADSs at a rate of 6.0118 ADSs per US$1,000 principal. The net proceeds, estimated at approximately US$485 million, will support various developmental activities including commercialization of TransCon hGH and clinical development of other products.
FAQ
What is the current stock price of Ascendis Pharma A/S American Depositary Shares (ASND)?
What is the market cap of Ascendis Pharma A/S American Depositary Shares (ASND)?
What is Ascendis Pharma A/S's primary focus?
Where is Ascendis Pharma A/S located?
What are some of Ascendis Pharma's key products?
In which regions does Ascendis Pharma operate?
What were Ascendis Pharma's total revenues for 2023?
What major milestones does Ascendis Pharma plan to achieve in 2024?
What is the Vision 2030 goal for Ascendis Pharma?
How much cash and marketable securities did Ascendis Pharma have at the end of 2023?
What technology platform does Ascendis Pharma use for developing its therapies?
What are Ascendis Pharma's core values?
